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Abstract
Background and objectivesActionable geneticfindings have implications for care of patientswith kidney disease,
and genetic testing is an emerging tool in nephrology practice. However, there are scarce data regarding best
practices for return of results and clinical application of actionable genetic findings for kidney patients.
Design, setting, participants, & measurementsWe developed a return of results workflow in collaborations with
clinicians for the retrospective recontact of adult nephrology patients who had been recruited into a biobank
research study for exome sequencing and were identified to have medically actionable genetic findings.
Results Using this workflow, we attempted to recontact a diverse pilot cohort of 104 nephrology research
participantswithactionablegeneticfindings, encompassing34differentmonogenic etiologiesofnephropathyand
five single-genedisorders recommendedby theAmericanCollege ofMedicalGenetics andGenomics for return as
medicallyactionable secondaryfindings.Wesuccessfully recontacted64 (62%)participantsandreturnedresults to
41 (39%) individuals. In each case, the genetic diagnosis hadmeaningful implications for the patients’ nephrology
care. Through implementation efforts and qualitative interviews with providers, we identified over 20 key
challenges associated with returning results to study participants, and found that physician knowledge gaps in
genomicswasa recurrent theme.We iterativelyaddressed thesechallenges toyieldanoptimizedworkflow,which
included standardized consultation notes with tailored management recommendations, monthly educational
conferences on core topics in genomics, and a curated list of expert clinicians for patients requiring
extranephrologic referrals.
Conclusions Developing the infrastructure to support return of genetic results in nephrology was resource-
intensive, but presented potential opportunities for improving patient care.
CJASN 15: 651–664, 2020. doi: https://doi.org/10.2215/CJN.12481019
Introduction
Massively parallel sequencing approaches, including
exome sequencing, are increasingly utilized in many
clinical disciplines, including in nephrology (1,2).
Recent studies have shown that exome sequencing
can pinpoint causal variants in 10%–35% of patients
with nephropathy (3–8). Importantly, a genetic diagno-
sis can support personalized care, including informing
targeted workup, disease prognosis, choice of therapy,
and/or family counseling (6,8). In addition, it may help
prioritize donor selection for transplantation among at-
risk family members. However, broader utilization of
genetic testing in routine clinical care raises a number
of technical, logistical, and ethical questions regarding
return of results.
To start, genetic testing may yield various types of
results. Beyond identification of a diagnostic finding
explicative of the patient’s condition, it may identify
variants of uncertain significance, which could prompt
additional clinical testing (9). Genome-wide sequencing
approaches may also uncover incidental or secondary
findings that, although unrelated to the primary test
indication, may nonetheless be medically actionable
(e.g., detection of predisposition to hereditary cancers or
cardiovascular disorders) (10) and also have implica-
tions for nephrology care (5,6). Furthermore, genetic
testing results can effect insurability and confidentiality,
which many patients and providers may not fully
realize. Ordering clinicians can often be expected to
understand the types of results that may emerge from
ordering a genetic test, provide patients pretest coun-
seling to ensure informed consent, and translate the
genetic findings into personalized care. However, be-
cause genetic testing is an emerging tool in nephrol-
ogy, physicians may lack the requisite knowledge
and infrastructure to effectively use clinical genetic




































www.cjasn.org Vol 15 May, 2020 Copyright © 2020 by the American Society of Nephrology 651
Return of results is further complicated when the initial
sequencing occurs in the research setting. The promise of
receiving medically relevant findings has encouraged more
patients to participate in genomic research (13,14), and
sparked calls to return research findings to study partic-
ipants (15). Investigators with existing biobanks and
archived data sets (16) whowish to return research findings
to study participants have had to update their protocols to
include an option for return of results, along with in-
corporating the requisite clinical standards into their
sequencing pathway to return research results. Impor-
tantly, in the United States, only test results obtained
through laboratories that meet federal quality standards set
by the Clinical Laboratory Improvement Amendments
(CLIA) of 1988 (17) can be applied to patient care. Thus,
research findings identified by research-grade sequencing
cannot be returned to patients unless they are confirmed
with clinical-grade testing.
Currently, the available data for optimal practices for
return of results in a research context, and for nephrology
patients, are highly limited and necessitate further study.
Here, we describe our experience returning medically
actionable genetic results to a diverse cohort of nephrology
patients, followed in a large urban tertiary medical care
center, who underwent research-grade genetic sequencing
through their participation in a biobank study.
Materials and Methods
Return of Results Workflow
We developed a return of results workflow for adult
research participants (aged $18 years) enrolled in Colum-
bia University’s Genetic Studies of CKD biobanking pro-
tocol with medically actionable genetic findings detected
by exome sequencing (5,6). The protocol was first updated
in January 2015 to include return of results. Actionable
findings included: primary diagnostic, defined as variants
classified as “pathogenic” or “likely pathogenic” per the
American College of Medical Genetics and Genomics
(ACMG) criteria (18) potentially explicative for patients’
nephropathy; and secondary, defined as known and
expected pathogenic variants in the 59 genes recommended
by the ACMG for return as medically actionable secondary
findings (10). We next identified participants with action-
able findings who opted for recontact. Primary diagnostic
findings underwent a rigorous two-part review process.
Each variant initially identified underwent a second review
by a team of nephrologists with expertise in hereditary
nephropathies and a molecular pathologist, to further
confirm their pathogenicity. We then examined these
participants’ electronic health records (EHRs) and consul-
ted with their treating nephrologist to verify that primary
diagnostic findings were indeed explicative of the patient’s
kidney disease.
In consultation with clinical nephrologists at our center,
the research team developed a standardized workflow
(Figure 1 and section S1 of the Supplemental Material),
which involved sending participants a letter on behalf of
their treating nephrologist informing them that a research-
level finding was detected and inviting them to come in
to discuss clinical genetic testing with the Precision Ne-
phrology fellow, an American Board of Internal Medicine-
certified nephrologist, and a member of the study team
who is bilingual (fluent in English and Spanish). Partici-
pants who did not respond after 30 days received up to two
telephone calls. Those who agreed to confirmatory testing
after pretest counseling provided written consent. A fresh
blood sample was then sent to the New York Genome
Center or Columbia University’s Personalized Genomics
Laboratory, clinically (CLIA) certified laboratories, for
targeted dideoxy terminator (Sanger) sequencing of the
variant(s) identified by exome sequencing. The referring
nephrologist was notified of patients where recontact was
not established.
A subset of biobank participants, enrolled in 2016, were
dually consented for research- and clinical-grade sequenc-
ing. Clinical sequencing was offered through the Electronic
Medical Records and Genomics (eMERGE) Network’s (19)
phase 3 study, where sequencing was performed on
the eMERGE-Seq platform, a next-generation sequencing
panel of 74 actionable genes (described in Section S1 of the
Supplemental Material). Because sequencing for these
participants was performed in a clinical-grade environ-
ment, participants with diagnostic findings identified on
exome sequencing, also identified on this panel, did not
require clinical retesting.
Clinically confirmed findings were returned by clinicians
specialized in the treatment of hereditary nephropathies.
The visit also included a comprehensive clinical evalua-
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Figure 1. | Developing a standardized workflow for return of
medically actionable genetic findings to nephrology research par-
ticipants. Optimization of a workflow for return of results in ne-
phrology: the workflow was iteratively developed on the basis of
feasibility and challenges encountered with return of results, along-
side provider feedback. The strategies implemented to address various
challenges faced with return of results informed the final optimized
workflow, which included five key steps: (1) genetic sequence anal-
ysis; (2) notifying the referring nephrologist; (3) participant recontact;
(4) return of clinically confirmed results with post-test counseling;
and (5) clinical application of findings.
652 CJASN
standardized clinical consultation note that detailed the
findings and management recommendations to share with
outside providers, along with a simplified note to share
with family members (Section S1 in the Supplemental
Material). These data were entered into the EHR after the
genetic findings were discussed with the referring
nephrologist.
The Cost of the Return of Results Workflow
To evaluate the fixed start-up cost for this pilot study, we
estimated direct labor costs of the research team, made up
of eight individuals (four faculty members, two research
scientists, a research staff member, and a research trainee),
along with other direct (e.g., clinical retesting, etc.) and
indirect costs (further detailed in Section S1 in the
Supplemental Material).
Clinical Implications of Return of Results
To explore the clinical effect of return of results, we
first differentiated between patients where the genetic
findings confirmed the suspected hereditary cause,
identified a molecular cause for an undiagnosed condi-
tion, reclassified the disease, or detected a variant di-
agnostic for an otherwise medically actionable condition.
Biobank participants with medically actionable genetic findings detected on exome sequencing
(N=213)
Screened out: 100
• Less than 18 years of age (22)
• Require reconsent (73)
• Did not opt for re-contact (5)




No response to communication: 32




Declined to continue: 16
• Prior knowledge of clinical diagnosis (3)
• Insufficient time (2)
• Lack of interest (8)




Declined to continue: 5
• Prior knowledge of clinical diagnosis (3)
• Insufficient time (1)
• No Show (1)
Participants who returned for results
(n=41) (n=35)
(n=6)
Declined to continue: 1
• Prior knowledge of clinical diagnosis (1)
Research findings not confirmed: 1
(n=7)
Potentially eligible adults included in pilot cohort
(n=104)Biobank participants dual enrolled in the
eMERGE Network's Phase Ill study
Genetic findings detected with research-
grade sequencing
(n=7 ) (n=97 )
Figure 2. | Results of piloting return of results workflow among genetic study research participants. The return of results study flow: we
identified 213 study participants with medically relevant findings. Of these participants, 113 were adults who opted for return of actionable
findings as part of their informed consent andwere eligible for thorough reviewof their electronic health record, an additional nine participants
wereexcludedas theyhadattainedageneticdiagnosis via clinical genetic testingoutsideof thisworkflow.The remaining104participantswere
all included in thepilot cohort.Of these 104participants, seven individuals (7%)weredual enrolled in the eMERGENetwork’s phase3 studyand
consented for clinical-grade sequencing on the eMERGE-seq platform. In total, we successfully recontacted 64 of the 104 (62%) participants,
including all seven individuals crossenrolled in the eMERGE study. Among the 48 individuals who consented for clinical-grade sequencing
(including the seven participants enrolled in eMERGE), 41 had their results returned byour nephrogenetics team. In one case, the research-level
findings were not confirmed due to a technical limitation of the confirmatory test modality used (detailed in Section S2 of the
Supplemental Material).
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For each case, we also examined the implications of
the genetically informed management recommendations
(e.g., specialty referrals, cascade screening, etc.). We also
met with referring nephrologists one-on-one and asked
them open-ended questions about their level of satisfac-
tion with the workflow. Their responses were documen-
ted in field notes.
Data Management
Study data were collected and managed using the
Research Electronic Data Capture (20) tool hosted by
Columbia University. Additional mechanisms for ensuring
data security and patient privacy were detailed in an earlier
publication (6).
Statistical Analyses
Baseline characteristics were described using counts and
percentages for categorical variables, and medians and
interquartile ranges (IQRs) for continuous variables. We
compared baseline sociodemographic and clinical data
of participants by their recontact status using a chi-squared
or Wilcoxon rank-sum test, as appropriate. All analyses
were performed using STATA version 15. We considered
P values ,0.05 as statistically significant.
Results
Characteristics of the Pilot Cohort
We initially identified 213 study participants with med-
ically relevant findings, the majority (205/213) of whom
were included in earlier publications (5,6). Of these par-
ticipants, 113 were adults who opted for return of action-
able findings as part of their informed consent and were
eligible for return of results (Figure 2 and section S2 in the
Supplemental Material). After EHR review, an additional
nine participants were excluded because they had at-
tained a genetic diagnosis via clinical genetic testing and
had their results returned outside of this workflow
[referring providers were notified that the same variant(s)
was identified on research-grade exome sequencing]. The
remaining 104 eligible adults were selected for
this pilot study.
The 104 pilot study participants (Table 1) had a median
age of 38 (IQR, 28.0–51) years and .50% (58%) self-
identified as white. Five participants (5%) were exclusively
Table 1. Clinical characteristics of the pilot cohort (n5104)





Number of participants 104 64 40
Age at time of study entry, yr
0–21 3 (3) 1 (2) 2 (5)
22–49 74 (71) 45 (70) 29 (73)
$50 27 (26) 18 (28) 9 (23)
Median (IQR) 38 (28–51) 40 (29–52) 35 (28–48)
Sex
Female 40 (39) 32 (50) 8 (20)
Race/ethnicity
White 60 (58) 45 (70) 15 (38)
Hispanic/Latino 22 (21) 10 (16) 12 (30)
Black 9 (9) 3 (5) 6 (15)
Asian 12 (12) 6 (9) 6 (15)
Other/unspecified 1 (1) 0 1 (3)
Study entry yr
Before 2010 7 (7) 2 (3) 5 (13)
2010–2014 18 (17) 13 (20) 5 (13)
2015–2019 79 (76) 49 (77) 30 (75)
Time from enrollment to recontact attempt, yr
Median (IQR) 2.9 (1.9–3.8) 2.4 (1.7–3.7) 3.3 (2.8–4.1)
Insurance category
Private 78 (75) 53 (83) 25 (63)
Public (including
Medicare, Medicaid)
26 (25) 11 (17) 15 (38)
Reached kidney failurea 42 (40) 21 (33) 21 (53)
Positive family history for
kidney disease
66 (64) 43 (67) 23 (58)
Clinical diagnosis
Congenital or cystic kidney disease 9 (9) 6 (9) 3 (8)
Glomerulopathy 54 (52) 33 (52) 21 (53)
Diabetic nephropathy 3 (3) 1 (2) 2 (5)
Tubulointerstitial disease 11 (11) 8 (13) 3 (8)
Nephropathy of unknown origin 26 (25) 15 (23) 11 (28)
Other 1 (1) 1 (2) 0
IQR, interquartile range.
Percentages do not all sum to 100% due to rounding.
aKidney failure includes patients on KRT and kidney transplant recipients.
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Spanish-speaking and the remainder were proficient En-
glish speakers. Over one-third (37%) of participants re-
ported no family history of kidney disease at the time of
enrollment. On the basis of their EHRs, 26 (25%) individ-
uals had public insurance (i.e., Medicare, Medicaid, or
both). One-half of the patients (52%) had a clinical di-
agnosis of a glomerulopathy; for 26 participants (25%), the
primary etiology of their kidney disease was unknown. In
addition, 42 (40%) individuals had reached kidney failure
at the time of study enrollment. The median interval
between time of enrollment and attempted recontact was
2.9 (IQR, 1.9–3.8) years.
Of the 104 participants, eight (8%) individuals had
findings in one of the 59 ACMG medically actionable
secondary genes (Table 2, Supplemental Table 1 in the
Supplemental Material). The remaining 96 participants had
primary diagnostic findings encompassing 34 distinct
single-gene etiologies. Of the 34 distinct monogenic ne-
phropathies in our cohort, the most recurrent primary
genetic findings were in COL4A3/4/5 genes associated with
type IV collagen-associated nephropathy, also known as
Alport syndrome.
Recontact and Return of Results
Of these 104 participants, seven (7%) were dual enrolled
in the eMERGE Network’s phase 3 study and underwent
clinical-grade sequencing. Fifty-seven participants were
recontacted for clinical retesting, whereas seven partici-
pants were recontacted for return of results (Figure 2). In
total, we successfully recontacted 64 (62%) participants,
including all seven individuals crossenrolled in the
eMERGE study. Inability to recontact was due to no
response to communication (n532) and out-of-date contact
information, such as invalid or disconnected telephone
number (n55). In addition, three participants were de-
ceased at the time of recontact. Participants successfully
recontacted (Table 1) were more likely to be female (50%
versus 20%, P50.002), white (70% versus 38%, P,0.001)
versus nonwhite, have private insurance (83% versus 63%,
P50.02) versus other, and experienced a shorter interval
between enrollment and recontact attempt (2.4 years; IQR,
1.7–3.7 versus 3.3 years; IQR 2.8–4.1, P50.001).
Of the 57 participants who were recontacted for clinical
retesting, 16 refused. Reasons for declining confirmatory
testing included lack of interest (n58), insufficient time
(n52), prior knowledge of the clinical diagnosis (here,
Alport syndrome, Gitelman syndrome, and Fabry disease;
n53), or relocation to another state (n53). Individuals who
moved away were referred to a local genetic counselor for
clinical genetic testing.
Among the 48 individuals who underwent clinical-grade
sequencing (including the seven participants enrolled in
eMERGE), 41 had their results returned by our nephroge-
netics team, including 21 males and 20 females, most of
whom self-identified as white (n529; 71%). Six individuals
failed to return for their results (Figure 2 and Section S2 of
the Supplemental Material). In one case, results were not
confirmed due to a technical limitation of the confirmatory
test modality used (described in Section S2 of the
Supplemental Material). The referring nephrologists were
notified of the findings and their confirmatory genetic
report entered in the EHR.
Clinical Implications of the Genetic Findings in
Nephrology Care
Disclosure of the genetic findings had direct implications to
the care of all 41 participants who received their results: the
results either confirmed the suspected hereditary cause
(n518), identified a molecular cause for an undiagnosed
condition (n513), reclassified the disease (n58), or identified
a genetic variant diagnostic for an otherwise medically
actionable condition (n52), (Table 2). Importantly, for over
one-half of the participants, the genetic diagnosis had
implications for therapy [e.g., use of thiazides for hyper-
calciuria in Dent disease (21), etc.] (n522; 54%), informed
clinical prognosis (e.g., risk for disease progression and/or
transplantation) (n529; 71%), and initiated subspecialty care
referrals for workup of associated extrakidneymanifestations
(n527; 66%). The referrals encompassed subspecialists span-
ning a wide range of clinical domains, including otolaryn-
gology, ophthalmology, cardiology, endocrinology,
hematology, breast oncology, and maternal–fetal medicine.
The genetic diagnoses guided familial testing of at-risk family
members of 13 (32%) individuals, and facilitated allograft
donor selection for eight (20%) participants.
With respect to otherwise medically actionable secondary
findings, the participant with a pathogenic variant in the
SCN5A gene, associated with Brugada syndrome 1/long QT
syndrome type 3, was referred to a cardiologist specialized in
cardiac electrophysiology for specialized diagnostic testing
and assessment for an automatic implantable cardioverter-
defibrillator (22). In addition, although not diagnostic of the
patient’s underlying glomerulopathy, the genetic finding had
implications for his nephrology care, including avoidance of
medications that prolong the QT interval, or deplete serum
magnesium and potassium levels (23) (e.g., verapamil, loop
diuretics, etc.), and increase the risk for sudden death. The
individual with a pathogenic BRCA2 variant, associated with
hereditary breast and ovarian cancer, was diagnosed with
breast cancer after an abnormal diagnostic mammogram
1 month before return of results. The genetic finding
ultimately led to cascade screening and prophylactic mas-
tectomies (24) in two of her daughters, who were found to
also harbor the mutation.
Lessons Learned from Return of Results
Over 20 major challenges were identified in implement-
ing the return of results workflow (Table 3). We iteratively
addressed these challenges to yield an optimized workflow
(Figure 1), which includes standardized consultation notes
with tailored management recommendations, monthly
educational conferences on core topics in genomics, and
a curated list of expert clinicians for patients requiring
extranephrologic referrals.
Cost of the Return of Results Workflow
The eight-member study team dedicated an estimated
1452 hours to Return of Results efforts over 31 months. The
fixed start-up cost for this pilot study was estimated to be
$92,249.31 (Supplemental Tables 2–5).
Discussion
We developed a return of results workflow for medically
actionable genetic findings emerging from research-grade
CJASN 15: 651–664, May, 2020 Return of Genetic Results in Nephrology, Nestor et al. 655




















Confirmed suspected hereditary cause (n518)
22–49 Glomerulopathy Pos NPHS1/Nephrotic syndrome type 1 (256300) Yes Yes No No No
22–49 Tubulointerstitial
disease
Pos CLCN5/Dent disease (300009) No Yes No No Yes
$50 Glomerulopathy Neg COL4A3/Alport syndrome, autosomal dominant/
recessive; thin basement membrane disease (104200,
203780, 141200)
No No Yes No No
22–49 Glomerulopathy Pos COL4A4/Alport syndrome, autosomal dominant/
recessive; thin basement membrane disease (104200,
203780, 141200)
Yes Yes Yes No No
22–49 Glomerulopathy Pos COL4A5/Alport syndrome, X-linked (301050) Yes Yes Yes Yes No
$50 Glomerulopathy Pos COL4A5/Alport syndrome, X-linked (301050) No Yes Yes No No
$50 Glomerulopathy Pos COL4A5/Alport syndrome, X-linked (301050) No Yes Yes No Yes
22–49 Glomerulopathy Pos WT1/Nephrotic syndrome type 4 (256370) Yes Yes No No No
22–49 Congenital or cystic
kidney disease
Neg EYA1/Branchio-oto-renal syndrome 1 (113650) No Yes Yes Yes Yes
22–49 Congenital or cystic
kidney disease
Pos EYA1/Branchio-oto-renal syndrome 1 (113650) Yes Yes Yes No Yes
22–49 Tubulointerstitial
disease
Neg SLC12A3/Gitelman syndrome (263800) Yes No No No No
22–49 Kidney failure of
unknown etiology
Pos MYH9/Epstein syndrome; Fechtner syndrome
(153650, 153640)
Yes Yes Yes Yes No
18–21 Glomerulopathy Pos INF2/FSGS 5 (613237) Yes Yes No Yes Yes
22–49 Tubulointerstitial
disease
Neg SLC5A2/renal glucosuria (233100) Yes No No No No
22–49 Congenital or cystic
kidney disease
Pos TSC1/Tuberous sclerosis-1 (191100)a Yes Yes Yes No No
$50 Kidney failure of
unknown etiology
Pos UMOD/Autosomal dominant tubulointerstitial kidney
disease, UMOD-associated (609886, 162000, 603860)a
No Yes No No No
22–49 Tubulointerstitial
disease
Pos UMOD/Autosomal dominant tubulointerstitial kidney
disease, UMOD-associated (609886, 162000, 603860)a
No Yes No Yes Yes
22–49 Tubulointerstitial
disease
Pos UMOD/Autosomal dominant tubulointerstitial kidney
disease, UMOD-associated (609886, 162000, 603860)a
Yes Yes No No Yes
Identified molecular cause for undiagnosed condition (n513)
22–49 Glomerulopathy Pos COL4A4/Alport syndrome, autosomal dominant/
recessive; thin basement membrane disease (104200,
203780, 141200)
No Yes Yes Yes No
22–49 Kidney failure of
unknown etiology
Pos COL4A5/Alport syndrome, X-linked (301050) Yes Yes Yes No No
$50 Glomerulopathy Pos COL4A5/Alport syndrome, X-linked (301050) No No Yes No No
22–49 Kidney failure of
unknown etiology
Pos CLCN5/Dent disease (300009) Yes Yes Yes No No
22–49 Kidney failure of
unknown etiology
Neg PAX2/Glomerulosclerosis focal segmental 7;
papillorenal syndrome (616002, 120330)



























$50 Kidney failure of
unknown etiology
Pos TRPC6/Glomerulosclerosis focal segmental 2 (603965) No Yes No No No
22–49 Kidney failure of
unknown etiology
Neg MC4R/Obesity, autosomal dominant (601665) Yes No Yes Yes No
22–49 Kidney failure of
unknown etiology
Neg APOE/Lipoprotein glomerulopathy;
hyperlipoproteinemia, type 3 (611771, 617347)
Yes Yes Yes No No
22–49 Glomerulopathy Neg CR2/FSGS 9 (616220) Yes Yes No Yes No
22–49 Congenital or cystic
kidney disease
Pos HNF1B/Renal cysts and diabetes syndrome (137920) No No Yes Yes No
$50 Tubulointerstitial
disease
Neg HNF1B/Renal cysts and diabetes syndrome (137920)a Yes Yes Yes No No
22–49 Kidney failure of
unknown etiology
Pos NPHP4/Nephronophthisis 4 (606966) No Yes Yes No No
22–49 Tubulointerstitial
disease
Pos UMOD/Autosomal dominant tubulointerstitial kidney
disease, UMOD-associated (609886, 162000, 603860)a
No Yes No No No
Reclassified disease (n58)
22–49 Glomerulopathy Pos COL4A3/Alport syndrome, autosomal dominant/
recessive; Thin basement membrane disease (104200,
203780,141200)
No Yes Yes Yes No
22–49 Glomerulopathy Pos COL4A4/Alport syndrome, autosomal dominant/
recessive; Thin basement membrane disease (104200,
203780,141200)
No No Yes No No
$50 Glomerulopathy Neg COL4A4/Alport syndrome, autosomal dominant/
recessive; Thin basement membrane disease (104200,
203780,141200)
No Yes Yes No No
$50 Glomerulopathy Pos COL4A4/Alport syndrome, autosomal dominant/
recessive; Thin basement membrane disease (104200,
203780,141200)
No No Yes No No
22–49 Kidney failure of
unknown etiology
Pos CLCN5/Dent disease (300009) Yes No Yes No No
22–49 Kidney failure of
unknown etiology
Pos CLCN5/Dent disease (300009) Yes Yes Yes Yes No
22–49 Glomerulopathy Pos SALL1/Townes–Brocks syndrome 1 (107480) No Yes Yes Yes Yes
$50 Glomerulopathy Pos TRPC6/Glomerulosclerosis focal segmental 2 (603965) Yes No No No No
Identified a genetic variant diagnostic for an otherwise medically actionable condition (n52)
22–49 Glomerulopathy Pos SCN5A/Brugada syndrome 1; long QT syndrome 3
(601144, 603830)
Yes No Yes No No
$50 Glomerulopathy Neg BRCA2/Hereditary breast and ovarian cancer (612555) Yes No No Yes No
Diagnostic utility is grouped by rows and clinical implications by columns. Neg, Negative; Pos, Positive.
aParticipants highlighted were crossrecruited into the eMERGE protocol (the ElectronicMedical Records and Genomics Network’s Phase III Study) and underwent clinical-grade sequencing as














































Table 3. Defining and refining a nephrology return of results workflow: key challenges encountered and solutions developed to
address them
Challenges Solution(s)
Protocol and consent amendment
IRB approval of original biobank study protocol to include
return of results mechanism
IRB amendment submission to include return of results
mechanism in studyprotocol and recontact option in consent form
Genetic data analysis
Guidelines needed for: On the basis of a group consensus:
Genes and/or types of genetic findings discovered in research-
setting that classify as “medically relevant” and are appropriate
for individual return to participants
Defined “medically relevant” genetic results appropriate for
return as diagnostic (primary) or otherwise medically actionable
(secondary) findings
Curated a relevant list of 625 genes associated with Mendelian
forms of genitourinary disease, to help prioritize variants for
analysis for diagnostic (primary) findings
Adopted a priori list of 59 genes deemed medically actionable by
the ACMG
Prioritization of candidate variants Developed a bioinformatics pipeline for diagnostic annotation of
exome variants
Obtained subscriptions to proprietary variant databases (e.g.,
Human Gene Mutation Database) to facilitate variant annotation
Determination of such variants as suitable for return to
nephrology patients
Collaborated with a molecular pathologist to review
pathogenicity of the findings
Establishedquarterly “nephrologygenetic sign-out rounds” for
interdisciplinary discussions on merits of variants of uncertain
significance/candidate variants. Attendance included: molecular
pathologists, nephrologists, kidney pathologists, and genetic
professionals
Initiated development of a pipeline to facilitate periodic
reanalysis of the sequence data as new genes and variants are
identified, and prior genetic findings are reclassified
Requested additional testing and further follow-up from
nephrologists on a case-by-case basis to further inform clinical
annotation and appropriateness for return
Working group to develop and oversee return of results needed Created multidisciplinary team (nephrologists, research
scientists, and a molecular pathologist focused on the
development of a return of results workflow
Participant recontact
Difficulty recontacting participants due to outdated contact
information
Modified biobank recruitment procedures to include additional
contact details (e.g., email, multiple telephone numbers, etc.) at
time of enrollment
Challenges expressed by nephrologists:
Lack of time to study recontact efforts Designated a nephrologist associated with the genetic
study to liaise between the research team and clinical faculty,
to facilitate recontact and return of results
Uncertainty on recontact procedures for study participants with
actionable research-level findings
Lackof confidence in their ability to counsel patients inquiringabout
research findings
Collaborated with referring nephrologists to optimize method
of recontact
Concerns regarding potential psychosocial effect and consequences
on participants recontacted for return of results
Concerns expressed by physicians, investigators, and genetics
professionals
Added comprehensive pretest and post-test genetic counseling
Included stakeholders’ viewpoints in the design of the return of
results workflow were included
Provided research staff with additional training on consent
procedures in order to:
Difficulty engaging participants to learn more about their
genetic findings
Empower research staff to inform potential participants of the
opportunities to learn about “medically relevant”geneticfindings
identified through the course of research
Encountered numerous participants requesting disclosure of their
preliminary research findings or study results outside the scope
of our analyses (e.g., ancestry, etc.)
Ensure all potential participants are informed that only
clinically-confirmed, actionable genetic findings (e.g., diagnostic
and/or secondary findings in the 59 genes recommended for
returned by the ACMG), are eligible for return
Additional training comprised of:
Formal didactic sessions
Mock recruitment sessions
Extended observerships with genetic counseling experts
Long lag times from original enrollment to return of results Leveraged opportunities to dual enroll biobank participants in
genomic studies where sequencing is performed in a clinically-
certified laboratory when possible, which reduced lag time from




Facilitated communications between genetic analysts and
return of results team using a centralized genetic database that
alerts the study team of actionable findings, further prioritizing
participants for recontact through the eMERGE study
Clinical genetic testing
Knowledge gaps expressed by physicians: Held educational conferences and didactics on core topics in
genomics for the clinical faculty with focus on:
Difference between clinical- and research-grade genetic testing Fundamental core concepts in genomic medicine
Interpretation of genetic test reports issued by commercial
laboratories
Types of data that may be generated in genetic research,
including medically actionable findings
Technical differences between research and clinical
laboratories, including federal requirements that only test results
generated from a laboratory certified under the CLIA can inform
patient care
Differences among diagnostic sequencing technologies (e.g.,
targeted sequencing, microarrays, exome sequencing, etc.),
including in scope, resolution, analytic sensitivity, alongwith their
respectivebenefits and limitations (e.g., limitations indetecting for
copy number variants and large structural variants with exome
sequencing, etc.), and the importance of periodic re-analysis
Methodology forvariant interpretationandclinical annotation
Pipeline for clinical confirmation of research-grade genetic
findings for our cohort needed
Identified CLIA-certified and New York State-approved
laboratories to performconfirmatory targeteddideoxy terminator
(Sanger) sequencing, with a rapid turn-around time
Identified additional commercial laboratories that offer
alternativemethods forvalidationof research-gradeexomedata in
the event of false negatives with targeted sequencing
Participants unable to return for clinical re-testing at our center
due to relocation to another state
Coordinated with the patient’s new primary nephrologist to
facilitate referrals to local genetic counselors
Assisted the new primary nephrologists in arranging
confirmatory genetic testing
Return of clinically confirmed results and post-test counseling
Patients express a lack of understanding of the clinical
implications of their genetic findings
Provided patients with a copy of the return of results
consultation note and CLIA-confirmed genetic test report
Referred patients for additional genetic counseling
Numerouspatients inquireabout futurepregnanciesandfamily
planning options
Curated a list of relevant patient support groups and
informational websites
Invited patients and their families to contact the nephrogenetics
team with additional questions
Identified maternal–fetal medicine specialists with genetic
expertise to referpatients forprenatal andpreimplantationgenetic
diagnostics counseling
Participants express need for guidance on how best to share the
genetic findings with their family members
Created a family letter template for patients to share with
family membersa
Clinical application of findings
Nephrologists express a need for greater understanding on the
next steps in management based on the genetic diagnosis
Drafted a detailed nephrogenetics consultation note that
includes management recommendations on the basis of the
genetic findings (see Section S1 of the Supplemental Material)a
Met one-on-one with referring nephrologists to discuss the
genetic findings and next steps (e.g., referrals, additional testing,
etc.) after the return of results visit
Need for a defined communication pathway for sharing the
genetic results and management recommendations with
additional providers
Addition to electronic health record:
Nephrogenetics consultation note
The CLIA-confirmed genetic test report
Corresponding ICD-10 code of the genetic diagnosis
Communicating with outside providers:
Invited outside providers to contact us to schedule additional
telephone consultations regarding their patient’s genetic findings
Provided participants with an electronic copy of the
nephrogenetics consultation note to share with any
additional providers
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exome sequencing of nephrology biobank participants. This
nephrology-specific workflow was iteratively developed to
address the challenges encountered integrating genetic se-
quencing into nephrology practice at a tertiary care referral
center. Using this workflow, we successfully returned results
to 41 nephrology patients across 23 single-gene disorders, and
observed howmedically actionable genetic findings can shape
management in nephrology care by informing choice of
therapy and prognosis [e.g., cautious use of diabetogenic
drugs such as tacrolimus and corticosteroids in patients with
Renal cysts and diabetes syndrome (HNF1B) who are at
increased risk for developing diabetes (25), greater risk for
antiglomerular basement membrane disease in allograft recip-
ients with Alport syndrome due to truncating variants in
COL4A5 (26), etc.], family counseling, and transplant donor
selection (Tables 2 and 4). In addition, we developed stan-
dardized communication materials to help surmount physi-
cian knowledge gaps, yielding a valuable resource for return of
results programs (See Section S1 of the SupplementalMaterial).
Prior return of results protocols have focused on the
return of actionable secondary findings to research
participants enrolled in population biobank studies. Sapp
et al. (27) utilized an a priori list of the then 56 genes deemed
medically actionable by the ACMG, whereas Schwartz et al.
(28) expanded on this gene set for a total of 76 genes for
return. Similarly, in addition to returning primary findings,
potentially explicative for individuals’ nephropathy, our
study returned medically actionable secondary findings in
the updated (59 genes) ACMG medically actionable genes,
making it, to our knowledge, the first study to return such
medically actionable secondary findings in the context of
clinical nephrology. Our experience returning ACMG 59
gene variants also reveals the global importance of sec-
ondary findings for patient care (Table 4, Supplemental
Table 6 in the Supplemental Material). For example,
hereditary cancer predisposition could favor modification
of the duration, intensity, or choice of immunosuppression
regimen, such as in the context of GN or transplantation.
Similarly, findings for hereditary cardiac arrhythmias may
support more vigilant electrolytes and volume status
management, and influence diuretic therapy and dialysis
prescriptions. Because approximately 1%–5% of unselected
Table 3. (Continued)
Challenges Solution(s)
Provided local nephrologists with:
Local nephrologists express need for guidance on next steps in
management on the basis of the genetic findings
Telephone consultation to assist in follow-up care for patients
no longer followed at our institution
Outline documenting clinical implications and management
recommendations relating to the genetic diagnosis, along with a
list of literature references and resources
Nephrologists express their need for guidance ordering clinical
genetic testing, asking:
Addition of a genetic counselor for the Division of Nephrology,
dedicated to guiding clinicians and patients on various clinical
genetic testing options, providing patients with pre-test
counseling, and informing clinicians about genetic implications of
the findings
Identified optimal commercial diagnostic laboratories for
different indications and provided nephrologists with estimates
of the out-of-pocket costs of different genetic tests (e.g., full cost for
aclinical exome foraprobandand trio; listprices for targetedcystic
kidney disease panels offered by different commercial
laboratories, etc.), and a list of laboratories offering financial
counseling and prior-authorization services, to guide their
selection of the most appropriate clinical genetic test
What genes to assess? Created nephrology-specific templates for Letter of Medical
Necessity for nephrologists to submit to insurance companies
when ordering clinical genetic testing, in order to facilitate their
requests for prior-authorizations by third-party payers
What test to order?
What commercial laboratory to choose? Established a weekly Nephrology Genetics clinic based on
the return of resultsworkflow for the evaluation andmanagement
of adult nephrology patients with a suspected hereditary
nephropathy or a new genetic diagnosis
Need for a referring mechanism for participants requiring
subsequent care based on primary diagnostic findings that
implicateadditionalorgansystemsand/orwithanotherwise
medically actionable (secondary) finding
Compiled a referral list of subspecialistswith genomic expertise in
relevant fields
Communicated the genetic findings to identified
subspecialists directly before the patient’s scheduled visit
(including for ophthalmology, otolaryngology, cardiology,
endocrinology, hematology, breast oncology, and
maternal–fetal medicine)
IRB, Institutional Review Board; ACMG, American College of Medical Genetics and Genomics; eMERGE, Electronic Medical Records
and Genomics Network’s Phase III Study; CLIA, Clinical Laboratory Improvement Amendments of 1988; ICD-10, The International
Statistical Classification of Diseases and Related Health Problems.
aAn example of the nephrogenetics consultation note and a template of the family letter can be found in Section S1 of the Supple-
mental Material.
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adults harbor such secondary findings (29,30), further
study is needed to assess their potential implications on
nephrology care and determine optimal approaches for
management. Moreover, our results support the impor-
tance of considering return of findings for non-nephrologic
disorders as otherwise medically actionable findings (i.e.,
secondary genetic findings of kidney significance).
Finally, our return of results program was resource-
intensive and the yield was modest, which is consistent
with prior studies. The success of return of results efforts
likely depends on the primary purpose of the study and the
interval since enrollment. Because our biobank protocol
was initially designed solely for genetic discovery, we
elected to revise our study and establish a workflow to
enable return of clinically confirmed, medically actionable
results, including in the ACMG 59 genes. Furthermore,
research funds covered the costs of these efforts, although
typically, the cost of confirmatory testing and follow-up
falls within the clinical domain. Overall, our study reflects
the evolution of translational research since the early 2000s,
and the known challenges incorporating requisite clinical
standards when merging research and clinical sequencing
in the genomic era (14). It is also in line with current
standards for genetic research, wherein investigators who
detect medically actionable findings in the course of
analyses, are expected to ensure that valid, clinically
confirmed results are communicated to study participants,
along with a plan for follow-up (15,31,32). Data suggests
that disclosure of genetic findings does not cause grave
psychologic distress in research participants (33–37) and
our findings emphasize that the detection of a monogenic
disorder, whether as a primary or a medically actionable
secondary finding, can meaningfully inform care. This
highlights opportunities for future research in precision
nephrology, and the importance of including return of
results mechanisms in the planning stages of investigations
that involve genetic sequence analyses and the possibility
of detecting medically actionable findings. Wider imple-
mentation of genetic testing in nephrology will also require
maintaining an up-to-date list of nephropathy-associated
genes, establishing best practice guidelines for periodic
sequence reanalysis, and for the return of variants of
Table 4. Examples of how genetic sequence data, along with clinical data, can be a valuable resource to guide personalized
management
Impact of Management Examples
Influence choice of therapy Recommended use of thiazides to reduce occurrence of nephrolithiasis in the setting of
hypercalciuria in patients with Dent disease (21)
Consideration for use of cyclosporine and RAAS blockade for the management of nephrotic
syndrome in patients FSGS/SRNS due to WT1 (42)
Consideration for immunosuppressionwith rapamycin in a transplant recipient identified tobe at
risk for a hereditary cancer syndrome (43)
Avoidance of tacrolimus and corticosteroids post-transplant in patients with renal cysts and
diabetes syndrome (HNF1B) to minimize risk of developing diabetes (25)
Consideration for RAAS blockade in males with X-linked Alport syndrome even before onset of
proteinuria (44)
Aggressive BP control in early ADPKD can slow GFR loss (45)
For lipoprotein glomerulopathy (APOE), management of proteinuria with fenofibrates [either
alone or in conjunction with other lipid lowering agents (46)] should be considered
Somatostatin therapy may be considered in patients with severe polycystic liver disease due to
ADPKD (47)
Inform prognosis Loss-of-function variants associated with early onset of kidney failure, hearing loss, and ocular
abnormalities in males and females with X-linked Alport syndrome (48,49)
Mostpatientswithbranchio-oto-renal syndrome (e.g.,EYA1,SALL1, etc.) havehearing loss,which
may be progressive (50)
There is ahigher risk for antiglomerularbasementmembranediseasepost-transplantationamong
patients with Alport syndrome due to a large deletion in the COL4A5 gene (26)
Initiate referral for
subspecialty care
Individuals with Alport syndrome should be referred for audiometry, ophthalmologic review,
retinal imaging, and, possibly, retinal optical coherence tomography (26)
Renal cysts and diabetes syndrome (HNF1B) patients should undergo imaging to screen for
chromophobe renal cell carcinoma (51)
Guide familial testing Cascade testing should be performed in at risk family members of an individual with X-linked
Alport syndrome (26)
Preimplantation genetic diagnostics should be included in the discussion of reproductive choices
among patients with ADPKD (52)
Assist with donor selection Mothers of affected males with Alport syndrome are discouraged from kidney donation because
of their own increased risk of kidney failure and hypertension, and predonation biopsy should
bemandatory to accurately determine the extent of damage and further discourage donation if
kidney damage is severe (44)
Patients with renal cysts and diabetes syndrome (HNF1B) should be considered for simultaneous
pancreatic and kidney transplantation (53)
Surveillance in patients with
secondary findings
Avoidance of medications that prolong the QT interval and/or deplete serum magnesium and
potassium levels (e.g., verapamil, loop diuretics, etc.) in patients with arrhythmogenic
hereditary syndromes (e.g., SCN5A, etc.) who may be at increased risk for sudden death (23)
RAAS, renin–angiotensin–aldosteronesystem;FSGS/SRNS, focal segmental glomerulosclerosis/steroid-resistantnephrotic syndrome;
ADPKD, autosomal dominant polycystic kidney disease.
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uncertain significance, developing efficient pipelines for
rapid and iterative variant evaluation as new genes and
variants are identified, and prior genetic findings are reclas-
sified (38), and obtaining third-party payer coverage for the
requisite follow-up care associated with detecting medically
actionable genetic findings. Addressing physician knowledge
gaps is also critical, and potentially met through strategies
that include the introduction of algorithms alerting clinicians
about a possible monogenic disease (39), development of
decision support tools for the EHR, and remote consultation
options for centers lacking genetic expertise (40) and/or the
resources required for return of results. Future studies will
need to comprehensively evaluate the relative diagnostic
yields between different genetic sequencing modalities and
the long-term effect of both primary and secondary genetic
findings on nephrology care, including on treatment deci-
sions, preimplantation genetic diagnostics, transplantation
eligibility, and third-party payer coverage. Further system-
atic study is also needed to examine ethical and legal
questions that may arise from return of results (41), and to
assess the long-term effect of the genetic findings on clinical
outcomes and healthcare utilization.
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Section S1- SUPPLEMENTARY METHODS 
 
Study design and protocol 
 
The Columbia University Medical Center (CUMC) Genetic Studies of Chronic Kidney 
Disease (CKD) (IRB #AAAC7385) is a genetic research and biobanking protocol 
(established in 2003; PI: Ali Gharavi) recruiting patients seen by the Division of 
Nephrology, and has been previously described1,2. In 2015, the study protocol and 
informed consent were revised for the first time to include the option for re-contact in the 
event a “medically relevant” finding was identified. Participants were also made aware 
that if there was a clinically actionable finding identified in the research laboratory, 
confirmatory re-testing in a Clinical Laboratory Improvement Amendments of 1988 
(CLIA)-certified laboratory would be necessary, using a newly collected blood sample. 
Beginning in January 2017, participants enrolled prior to January 2015, were met by a 
member of our research team at one of their subsequent nephrology follow-up 
appointments and given the opportunity to reconsent to participation with this new 
clause included. This required additional amendments to the IRB. 
 
The workflow was iteratively developed based on feasibility, challenges encountered 
with the introduction of Return of Results in nephrology care, alongside provider 
feedback. The strategies implemented to address various obstacles faced with Return 
of Results informed the final optimized workflow. 
 
The optimized final workflow: 
 
1. Genetic Sequence Analysis 
 
We developed an in-house pipeline to analyze sequence data for patients enrolled in 
our genetic biobank study. The major steps included exome sequencing, bioinformatics 
processing, variant annotation and sequence interpretation, and are detailed in our 
earlier publications1, 2.  
 
Exome sequencing (ES): 
ES data was captured using: the Agilent SureSelectXT Human All Exon V4 (51 Mb) kit1, 
yielding mean sequence coverage 110x, with on average 99% of target bases in a given 
sample achieving at least 10x coverage; or Roche NimbleGen SeqCap Exome EZ v3.0 
kit or the IDT xGen Exome Research Panel v1.0 kit2,  yielding mean sequence 
coverage 111x, with on average 97% of target bases in a given sample achieving at 
least 10x coverage. These coverages are in the range of those achieved using 




Gene- and variant-level prioritization:  
To facilitate identification of variants potentially causal for nephropathy, we manually 
curated a list of 625 genes associated with Mendelian forms of genitourinary disease6. 
The list was generated by querying the Online Mendelian Inheritance in Man (OMIM)7 
and Orpha.net8 databases for genes associated with Mendelian forms of kidney and 
genitourinary disease, followed by manual review of the primary literature to assess the 
strength of evidence supporting each gene-disease association and characterize the 
relevant molecular genetic and clinical attributes of the gene-disease pairs.  
 
Actionable findings included: primary diagnostic-variants classified as Pathogenic or 
Likely Pathogenic per the American College of Medical Genetics and Genomics 
(ACMG) criteria9 potentially explicative for patients’ nephropathy; and secondary-known 
and expected pathogenic variants in the 59 genes recommended by the ACMG for 
return as medically actionable secondary findings10.  
 
Case-level interpretation:  
We next identified participants with actionable primary (diagnostic) or secondary 
findings who opted for re-contact if a “medically relevant” findings were detected. To 
verify that primary diagnostic findings were indeed explicative of the patient’s kidney 
disease, we conducted an in-depth review of these participants’ electronic health 
records. This involved summarizing the individual’s clinical history and relevant data 
(e.g., biochemical studies, imaging and histopathology). Then, we consulted with their 
referring nephrologist to discuss the individual’s phenotype. Each variant selected for 
return also underwent secondary review by a team of nephrologists, research scientists, 
and a molecular geneticist to confirm its pathogenicity. 
 
2. Notify referring nephrologist 
 
In this study, we did not return Variants of Uncertain Significance to patients or 
providers. Such cases were routinely presented to the referring nephrologist during 
quarterly “Nephrology Genetic Sign Out Rounds”. In these conferences, the genetic 
findings were assessed in the clinical context with the patient’s provider. Additional 
testing (e.g., urine studies for a patient with a suspicious variant detected in CLCN5 
which is associated with Dent disease, etc.) and further follow-up were at times 
requested for these “candidate variant(s). If additional testing yielded data that was 
compelling enough to make the variant diagnostic (i.e., Pathogenic or Likely Pathogenic 
by the ACMG criteria), the provider was updated accordingly. Furthermore, as part of 
the workflow, sequence data is routinely re-analyzed as new genes and variants 
continued to be discovered. 
 
Adult (aged ≥ 18) participants of the aforementioned parent study with actionable 
genetic variants detected on research-grade exome sequencing (ES)1,2, who opted to 






3. Participant Re-contact  
 
Following initial revisions to the biobank study protocol in January 2015, pre-pilot efforts 
began in 2015 through 2016 to re-contact participants for Return of Results, beginning 
with the first 5 adult participants identified to be eligible. For these initial cases, we 
notified the referring nephrologists of the preliminary finding and recommended them to 
order clinical testing for confirmation of the research results. Providers expressed to us 
their concerns. Specifically, they cited not knowing how and from where to order clinical 
genetic testing, limited time in their clinical workflows to counsel patients on the benefits 
of confirming the genetic findings, and a lack of confidence in their ability to discuss 
research findings recommend clinical testing without disclosing the genetic variant, and 
adequately explaining the risks and benefits of clinical genetic testing. Therefore, we 
asked the nephrologists how they would like their patients who participated in the 
biobank protocol to be re-contacted in the event they were identified to have an 
actionable finding, and they expressed their preference for a clinician member of the 
study protocol to laisse between the research team and the clinical faculty. Therefore, 
the remaining individuals of the pilot cohort (99/104) were re-contacted by the Precision 
Nephrology Fellow, a trainee of the Division’s nephrology fellowship program, who 
continues to work alongside the clinical faculty as a practicing clinician, and a member 
of the Gharavi laboratory. The Precision Nephrology Fellow re-contact the majority of 
participants (99 of 104) in the pilot cohort, between January 2017 and July 2019.   
 
After alerting the referring nephrologist that a research-grade medically relevant finding 
was detected in their patient, study participants were re-contacted by the study team to 
notify them that a clinically actionable finding was identified and would require 
confirmation using a new secondary sample for clinical re-testing in a CLIA-certified 
laboratory before the findings could be disclosed. The initial re-contact method utilized 
by the study team was a telephone call to the participant alerting them that an 
actionable research-level finding was detected and inviting them to return to CUMC for 
a pre-test counseling visit and the opportunity to clinically validate the research findings. 
The telephone call was placed by a nephrologist on the study team (initially M.M., then 
after January 2017, J.G.N., the Precision Nephrology Fellow, who is an American Board 
of Internal Medicine-certified nephrologist who is bilingual in Spanish and English). 
Midway through the study, feedback from providers revealed their concerns, which 
included a physician’s responsibility to notify patients of potentially actionable findings, 
possible psychosocial impact of the genetic findings on patients and families (e.g., 
anxiety, depression, stigmatization, loss/increase cost of insurance coverage, etc.), 
desires to respect the rights of some patients to no longer want to know about the 
genetic findings, and their inability to proper instruct patients who contacted them with 
questions or concerns after receiving the telephone call. Thus, the nephrologists 
suggested notifying participants with a letter, instead of a telephone call. The re-contact 
letter was developed in collaboration with the clinicians and approved by the Institutional 
Review Board (IRB). The letter was sent to the remaining eligible participants along with 
an enclosed “refusal form” that participants could complete and return (using the self-
addressed stamped envelope included with the letter) to the research team if they were 
not interested in learning more about the genetic findings. Based on the mixed response 
 
 
rates from either re-contact method, we adopted a standardized re-contact approach for 
the return of results workflow: sending the re-contact letter (see Re-contact Letter), 
followed by up to two subsequent telephone calls (see Re-contact Telephone Script) 
to all participants the who did not respond after 30 days. This standardized approach 
was utilized for 21 pilot participants. We made reasonable efforts to re-contact 
participants, consistent with recent consensus statements 11-13. In cases where we were 
unable to re-contact the study participant by telephone or by mail correspondence, the 
Precision Nephrology Fellow notified the referring nephrologist, and requested their 
assistance contacting the participant. The nephrologists often had insight on the status 
of the patient (e.g., deceased, relocated, etc.). The patient was considered lost to 
follow-up if these measures failed.  
 
 
Pre-test counseling and clinical re-testing for participants who underwent 
research-grade exome sequencing: 
 
Pre-test counseling consisted of an in-person visit, with the Precision Nephrology 
Fellow, that typically lasted approximately 30 minutes. During this visit, participants 
were reminded that the research-grade findings required re-testing for CLIA-
confirmation before the results could be disclosed as they were not-yet validated. They 
were also given an in-depth overview of the potential risks and benefits of clinical (CLIA-
certified) genetic testing including limitations of genetic tests (e.g., varying resolution 
and analytic sensitivity between modalities), variant interpretation and shifting 
classification based on periodic reanalysis, potential loss of privacy, and federal 
protections against genetic discrimination provided through the Genetic Information 
Nondiscrimination Act (GINA). Discussions were tailored to the participant based on 
their perceived knowledge gap and health literacy, and the category of their genetic 
finding (e.g., primary diagnostic versus medically actionable secondary findings), to 
ensure their informed consent. 
 
Following these discussions, written consent was obtained from participants who opted 
for clinical re-testing. A new blood sample was collected and participants were 
immediately scheduled for their second in-person visit, for post-test counseling visit, 
approximately eight weeks later. The option to schedule the follow-up post-test 
counseling visit during the pre-test counseling encounter was intended to facilitate the 
process of scheduling the appointment for the participant. When participants’ expressed 
concerns returning for a second visit or reported a scheduling conflicts, efforts were 
made Precision Nephrology fellow to minimize additional travel to the hospital. This 
included rescheduling participants’ other appointments (e.g., medical appointments, 
procedures, treatments, etc.) so that they may fall on the same day as the Return of 
Results visit.  
 
A second blood sample was then sent to the New York Genome Center (NYGC) or to 
Columbia University’s Personalized Genomics Laboratory for clinical-grade targeted 
dideoxy terminator (Sanger) sequencing of the variant(s). Early on, providers expressed 
concern about possible high out-of-pocket costs to patients who pursue clinical genetic 
 
 
testing to confirm the research findings. Therefore, to prevent financial limitations 
impacting the participants’ decision to validate the research findings, the Division’s 
research funds covered the full cost of CLIA-sequencing* for this pilot cohort. 
 
*Note- this may not be a scalable solution with further expanded use of genetic testing. To 
address this, other strategies we implemented in our workflow included procedures to 
facilitate providers’ efforts to pursue prior authorizations with the insurance companies and 
to inform their decision on ordering clinical genetic testing. 
They included: 
1. Development of a templated “letter of medical necessity” for providers suspicious of a 
hereditary nephropathy and interested in ordering clinical genetic testing 
2. Providing nephrologists with estimates of the full cost of different genetic tests (e.g., 
clinical grade ES for probands and trios; cost of a targeted cystic kidney disease panel 
through different commercial laboratories, etc.) 
3. Alerting providers of which commercial laboratories offer financial counseling and prior-
authorization services and can offer estimates of out-of-pocket costs and likelihood of 
insurance coverage 
4. Leveraging opportunities to do increasingly conduct research-level sequencing within a 
CLIA-certified environment 
 
For patients who had relocated out-of-state and unable to return for clinical re-testing, 
efforts would be made to assist them in finding a genetic counselor locally so that they 
may order the appropriate confirmatory genetic testing. 
 
Clinical-grade genetic testing through participation in the eMERGE study: 
 
In 2016, a subset of biobank participants was dually consented for research-grade and 
clinical-grade sequencing. Clinical sequencing was offered through their participation in 
the Electronic Medical Records and Genomics (eMERGE) Network’s Phase III study, 
where sequencing was performed using the eMERGE-seq platform, a next generation 
sequencing (NGS) panel of 74 actionable genes.  
 
Clinical interpretation for the eMERGE Network for our recruitment site was at Baylor 
College of Medicine (CAP# 8004250/CLIA#45D2027450). Using the eMERGE-seq 
Version 2 NGS Panel, Baylor cited the following quality control metrics of the 
sequencing data: > 70% of reads aligned to target, >99% target base covered at > 20x, 
> 98% target base covered at > 40x, average coverage of target bases > 200x. Baylor 
provided Columbia University with clinical interpretation for variants classifies as 
Pathogenic and Likely Pathogenic per the ACMG criteria9, for the following 74 genes: 
ACTA2, ACTC1, APC, APOB, ATM, BMPR1A, BRCA1, BRCA2, CACNA1A, CACNA1S, 
CFH, CHEK2, COL3A1, COL5A1, DSC2, DSG2, DSP, FBN1, GLA, HNF1A, HNF1B, 
KCNE1, KCNH2, KCNJ2, KCNQ1, LDLR, LMNA, MC4R, MEN1, MLH1, MSH2, MSH6, 
MUTYH, MYBPC3, MYH11, MYH7, MYL2, MYL3, MYLK, NF2, OTC, PALB2, PCSK9, 
PKP2, PMS2, POLD1, POLE, PRKAG2, PTEN, RB1, RET, RYR1, RYR2, SCN5A, 
SDHAF2, SDHB, SDHC, SDHD, SMAD3, SMAD4, STK11, TGFBR1, TGFBR2, 




As sequencing for these participants was performed in a clinical-grade environment, 
participants with diagnostic findings (putative variants in kidney-related genes) identified 
on ES, also identified on this NGS panel, did not require the additional step of clinical 
re-testing. These patients were re-contacted by letter and up to 2 follow-up telephone 
calls after 30 days. However, these patients were instead invited for a Return of Results 
visit with the nephrogenetics team.  
 
4. Return of clinically confirmed results and post-test counseling 
 
In this Return of Results visit, the nephrogenetics team, consisting of the Precision 
Nephrology fellow and a senior faculty member with expertise in hereditary forms of 
kidney disease (A.G.G, K.K., S.S.C.), met with patients to provide post-test counseling 
and a comprehensive clinical consultation. After in-depth review of the clinical and 
familial histories, and physical examination, the confirmed genetic findings were 
disclosed. Inheritance, cascade screening and family counseling options were 
discussed in details. The implications of the genetic findings (whether primary 
diagnostic or medically actionable secondary findings) were then explained to the 
patient, in the context of their kidney disease. This comprehensive consultation typically 
lasted 60 minutes. Participants received a standardized clinical consultation note that 
detailed the genetic findings and listed the management recommendations (see 
Nephrogenetics Consultation Note Template), along with a copy of the CLIA-
confirmed variant report for them to share with their providers and family members. 
Whenever indicated, we also provided participants with a simplified informational note to 
share with at-risk family members (see Family Letter), that included the variant(s) 




In the event a participant relocated, and chose to undergo confirmatory genetic testing 
locally, steps were included to support the new local nephrologists with Return of 
Results using telephone consultations with the provider, the patient, and/or both parties. 
A detailed summary of the discussions would then be sent to the local nephrologist 
outlining the management recommendations based on the genetic diagnosis.  
 
 
5. Clinical application of findings  
 
After the Return of Results visit, the genetic diagnosis, along with tailored medical 
management and referral recommendations, were reviewed one-on-one with the 
referring nephrologist. Individuals with actionable secondary findings were also referred 
to the appropriate specialist for subsequent care. An expert referrals list was developed 
that included genetic counselors, clinical geneticists and field experts (e.g., genetic 
ophthalmology, oncologists specialized in hereditary cancer syndromes, a genetic and 
maternal-fetal medicine expert, etc.). The consultation notes, and the CLIA-confirmed 













Dear [PATIENT NAME], 
 
On [DATE], you volunteered to participate in our genetic study. The research team has informed me that there 
may be findings that may be relevant to your health. However, New York State requires confirmation of 
research results by a clinically-certified (CLIA*) laboratory before they are given to you.   
 
If you are interested in learning more about the option to confirm this finding, you can schedule a free visit with my 
research colleague, [PROVIDER].  
 
[PROVIDER] will help with arranging for confirmatory testing, which involves a repeat blood draw. The repeat 
testing in an outside clinically-certified (CLIA) laboratory is voluntary and takes approximately 6-8 weeks. CLIA-
confirmed results will be discussed with you in person. Confirmed results will also be added to your medical record so 
that you and your physicians can refer to them in the future.  
 
Please note, the test to confirm the research result is free of charge for individuals who choose to participate in the 
Return of Results Study. This study requires participants to provide informed consent and is intended to help us 
develop best practices for sharing genetic results with our patients.  
 
Please call XXX-XXX-XXX to schedule a free visit to meet [PROVIDER]. If you have any questions, please feel free 
to call us or email us [TELEPHONE NUMBER; EMAIL ADDRESS]. 
 
If you do not want to learn more about how to confirm the research findings, please complete the attached form 







*The Clinical Laboratory Improvement Amendments (CLIA) of 1998 regulates that all clinical laboratories be 
certified by their state and the Center for Medicare and Medicaid Services (CMS), to ensure they meet the highest 







Re-contact Telephone Script 
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Attached to Protocol:         
Principal Investigator:         




STEP 1: Calling the Potential Participant 
 
Hello, I am ___________________________________________ from the Department of Medicine at 
[INSTITUTION].  May I please speak to_________________________? 
 
If desired person is not 
available: 
Is there a better day and time to reach (Mr. / Ms.)__________________________? 
 
➢ Note days and times:_____________________________________________ 
 
Thank you. I will call back then. 
 
➢ End call 
 
When desired person 
gets on the phone: 
 
Hello (Mr./Ms.) ___________________.   
I am ___________________________________________ from the Department of  
             name of authorized study team member 
Medicine at [INSTITUTION].  
 
We are contacting you to follow-up on a letter sent to your home by Dr. [NAME 
OF THE TREATING NEPHROLOGIST].  
 
Did you receive that letter? 
 
➢ IF NO, go to STEP 2a 








Patient states they did 
not receive the letter 
 
Ok, the letter we sent stated that you previously volunteered to participate in one of 
our genetic studies and chose the option to be contacted if your preliminary results 
suggested the need for confirmatory testing. Dr. [NAME OF THE TREATING 
NEPHROLOGIST] has been notified by the research team that you have 
preliminary genetic results, which may be important to your health. But the results 
must first be confirmed in a special CLIA lab before they can be shared with you 
and with Dr. [NAME OF THE TREATING NEPHROLOGIST], and that requires a 
repeat blood test for confirmatory testing. 
 
Confirmatory testing is voluntary and if you would like to learn more about it, we 
invite you to come in and meet with [XXX], one of our physicians. She can discuss 
confirmatory testing with you in more detail. The visit with her is free. And if you 
decide that you would like to do the confirmatory testing when you meet with her, 
the results take about 6 to 8 weeks to get back. Plus, we offer to pay the cost for the 
CLIA test for those who agree to take part in our return of results study, which 
involves completing questionnaires about your opinions on genetic testing.   
 
 
Telephone Recruitment Script  
Page 2 of 3 
Would you like to come in and meet with [XXX]?   
➢ IF NO, go to STEP 3a 




Patient states they did 
receive the letter  
 
Good. Then as you know, Dr. [NAME OF THE TREATING NEPHROLOGIST] 
was notified by the research team that you have preliminary genetic results that 
may be important to your health, but the results must be confirmed with a repeat 
blood sample before they can be shared with you and with Dr. [NAME OF THE 
TREATING NEPHROLOGIST]. 
 
Confirmatory testing is voluntary and if you would like to learn more about it, we 
invite you to come in and meet with [XXX] one of our physicians. She can discuss 
confirmatory testing with you in more detail. The visit with her is free. And if you 
decide that you would like to do the confirmatory testing when you meet with her, 
the results take about 6 to 8 weeks to get back. Plus, we offer to pay the cost for the 
CLIA test for those who agree to take part in our return of results study, which 
involves completing questionnaires about your opinions on genetic testing.   
 
 
Would you like to come in and meet with [XXX]?   
➢ IF NO, go to STEP 3a 
➢ IF YES, go to STEP 3b 
 
 




IF interrupted or strong 
immediate refusal 
 
No problem, but may I ask why not? 
 
➢ Write down response given for why patient is not interested in coming in to 
meet with [XXX] to discuss the option to undergo confirmatory genetic testing 
________________________________________________________ 
 
➢ If no reason is provided, give the following options: 
❑ No time    
❑ Too stressful 
❑ I don’t want to learn this information 
❑ Other (please specify): ________________________________________________________ 
 
 
Thank you for your time, (Mr./Ms.) PATIENT NAME. Please call us at 







Great. What day would you like to come in?  
➢ Note day and time:________________________________________________ 
 
 
Thank you for your time, (Mr./Ms.) PATIENT NAME. Please call us at 
[TELEPHONE] if you have any questions. 


























Date of Birth: 
Date of Encounter: 
 
Referring Nephrologist: 
Primary Care Physician: 
 
Reason for Consultation: NAME OF INDEX is a 57-year old female with long standing hematuria, 
subnephrotic range proteinuria and CKD V presenting today for a return of genetic results visit.  
 
Clinical History: 
History of Present illness- 
[SUMMARIZED]  
 
In November of 2015, the patient presented to Columbia University for a second opinion as her renal 
insufficiency progressed. [PROVIDER NAME] suspected the patient had a hereditary glomerulopathy, but 
the etiology remained unknown. She was managed conservatively with RAAS blockade (lisinopril 40mg 








A. Imaging studies: Renal ultrasound from [DATE} reviewed, unremarkable 
B. Relevant laboratory studies: [DETAILED] 
C. Histopathology:  
Renal biopsy [ACCESSION #] [ORIGINAL DATE] 
Performed at INSTITUTION, re-read at Columbia University by [PATHOLOGIST NAME] on [DATE]  
1. Glomerulosclerosis with diffuse GBM thinning 
2. Tubular atrophy, interstitial fibrosis & interstitial inflammation 
3. Arterio- & arteriolosclerosis 
D. Other studies, including prior genetic testing: N/A 
 
Family History: 
Father- hearing loss and advanced CKD 
The patient reports her father never went on to require RRT and passed away in 2010 at the age of 72 
from “heart failure” 
 
Mother- currently alive at age 78, with hypercholesterolemia 
 
Sister- currently alive at age 51, with hearing loss as reported by the index 
 
Brother-currently alive at age 51, with no known medical problems  
 
Social History: 
Works as an executive administrator 
Has no children 
Lives alone 
Denies toxic habits 
 
Physical Exam: 
BP 139/87 mm Hg (upright) 
No dysmorphologies noted on exam 
 
Genetic Workup: 
The patient was enrolled in the Genetic Studies of Kidney Disease-a genetic studies and biobanking 
protocol on [DATE]. On research-grade exome sequencing, she was found to be heterozygous for a 
variant in the Collagen, Type IV, Alpha-A (COL4A5) gene. These findings were confirmed by targeted 




The patient was found to have a novel missense variant in COL4A5:c.3017G>A:p.G1006D. Putative 
variants in the COL4A5 gene are associated with X-linked Alport syndrome (OMIM Phenotype MIM 
#301050). The variant was classified as Likely Pathogenic under current American College of Medical 
Genetics and Genomics (ACMG) guidelines for clinical sequence interpretation (Richards et al., 2015) 
based on the following: 
The variant occurs at a highly conserved glycine residue in the triple helical domain, a known functional 
domain of the collagen protein (PM1). It is absent in large control population databases, including 
gnomAD and DiscoverEHR (PM2), and is a novel missense substitution at the same amino acid residue as 
previously reported pathogenic variant, p.G1006V. The p.G1006V was found segregating in family (2 
generations; 5 members: 2 unaffected, 3 affected) with a milder form of Alport Syndrome: affected 
members displayed hematuria and hearing loss, and did not report visual impairment (Barker et. al., 
2001) (PM5). The variant is a missense variant in a disease where missense mutations are a known 
mechanism of disease (i.e., Gly-Xaa-Yaa substitutions are a well-established mechanism of COL4A- 
associated nephropathy) (PP2) and was predicted to be deleterious by multiple in silico algorithms, 
including CADD, Polyphen-2-HumVar, SIFT, and MetaSVM (PP3). Finally, the patient’s clinical 
presentation and family history are highly specific for COL4A-associated nephropathy/Alport syndrome 
(PP4).  
The genetic findings detailed above, along with the patient’s clinical course and family history, strongly 
support a genetic diagnosis of X-linked Alport syndrome, a subtype of COL4A-associated nephropathy.  
Therapeutic Implications: 
COL4A-associated nephropathy encompasses a wide spectrum of clinical phenotypes, including isolated 
FSGS and Alport syndrome (X-linked and autosomal forms) (Stokman et al., 2016). Disease severity 
similarly varies within Alport spectrum phenotypes, ranging from isolated microscopic hematuria with 
stable renal function, to early- onset end-stage-renal disease (ESRD) with visual and auditory 
impairment.  
Among individuals with X-linked Alport syndrome, ESRD can occur anytime between the second and 
sixth decades of life, with varying degrees of hearing loss and ocular changes. As obligate heterozygotes, 
females generally show a milder disease course than affected males. However, studies to date have 
demonstrated that over 95% of females develop hematuria, 8-30% develop ESRD, and up to a third (4-
40%) having sensorineural hearing loss (Savige et al., 2013; Tan et al., 2010; Dagher et al., 2001; Jais et 
al., 2003). The type of putative variant may also modulate disease severity. Though loss-of-function 
variants in COL4A3/4/5 genes are generally associated with more severe disease compared to missense 
variants (e.g., later onset of ESRD, less frequent and less severe audiologic and ocular involvement) 
(Bekheirnia et al., 2010; Savige et al., 2016), interruptions of the glycine helix, such as in the case of the 
patient’s genetic findings, are also disruptive, which is consistent with the patient’s advanced CKD and 
subjective hearing loss.  
Given the patient’s progressive decline in renal function, we recommend that she undergo evaluation 
for renal allograft transplantation. Determination of inheritance information is important in this patient 
who is considering living-related donors, potentially from her sister (first choice) and her brother 
(second choice). We therefore recommend additional genetic screening of her mother and siblings 
(father is deceased) to confirm the inheritance of the COL4A5 variant and have referred the patient for 
additional genetic counseling.  
Finally, we recommend that the patient undergo formal ophthalmologic evaluation, informing the 
ophthalmologist that she has Alport syndrome. We also recommend formal audiologic evaluation given 
her reported subjective hearing loss. The patient will be referred to [PROVIDER NAME] in the 
Department of Ophthalmology’s Genetic Eye Clinic and to [PROVIDER NAME], an otolaryngologist with 
expertise in Alport syndrome.  
Family Counseling: 
The patient has no children. However, as we explained to her, we suspect she has a X-linked disease, 
meaning that this variant was transmitted to her by her father. In X-linked disorders, all female offspring 
of affected males are obligate carriers. We recommend that the patient’s sister, undergo thorough 
evaluation with a nephrologist, as well as genetic testing; if the sister is found to have the same COL4A5 
variant, we also recommend she undergo formal ophthalmologic and audiologic evaluations.  
As a reportedly healthy middle-aged adult male, the patient’s brother, is unlikely to have the same 
putative variant. Nevertheless, we recommend he also undergo a comprehensive evaluation with a 
nephrologist, as he is a possible renal donor.  
Incidental Findings: Not applicable 
  
Continuous review: Not applicable 
 
Variant Details: Gene: COL4A5 (OMIM Gene # 303630)  
RefSeq Transcript: NM_000495 (Build: GRCh37/hg19) Exon: 35 
gDNA change: chr.X:g.107868935G>A 
cDNA change: c.3017G>A  
Peptide change: p.G1006D  
Zygosity: Heterozygous 
Disease Association: X-linked Alport Syndrome (OMIM Phenotype MIM # 301050)  
 
Summary: 
This is a 57yo F with long standing hematuria, subnephrotic range proteinuria and glomerulosclerosis 
with GBM thinning noted on renal biopsy. She reports longstanding subjective hearing loss and has a 
family history of renal disease and hearing loss (father). On clinical-grade targeted testing, the patient 
was found to have a LP variant in the COL4A5 gene, deemed diagnostic for X-Linked Alport syndrome in 
a female. Given her advanced CKD, the patient should be evaluated for transplantation, and that her 
sister undergoes genetic screening as part of their donor evaluations.  
 
 
Physician To-Do List: 
1. Referred for transplant evaluation 
2. Referred to [PROVIDER NAME] for genetic counseling and cascade screening 
3. Referred to [PROVIDER NAME] in the Department of Ophthalmology 













To Whom It May Concern: 
 
The purpose of this letter is to inform you that an inherited genetic condition was identified in a 
member of your family. We recommend showing this letter to your primary care provider.  
A genetic risk factor for <Disease Name> was identified in a member of your family. Any blood-
related family member (parents, siblings, aunts, uncles, cousins, grandparents) may have the same 
genetic risk factor.  
 
Here is the technical information about the genetic risk factor identified in your family member: 
Disease Inheritance Gene Positiona Variant Zygosity Notes Interpretation 
<Disease Name>  <Gene 
Name> 
     
aNCBI ____ 
 
Here are some common questions to help you to better understand: 
1. What effect does this genetic risk factor have? 
This genetic risk increases individuals’ chance to develop <Disease Specific Risks>. 
Not all individuals with this risk factor will develop the condition. You and your family member may or 
may not have already developed this disease. 
2. How likely am I to have the genetic risk factor? 
This genetic risk factor is transmitted from parents to children. Children and siblings of people with 
this genetic risk factor have a chance to also have it. If a person does not have the genetic risk factor, 
then they cannot pass it on to their children. Based on our discussion with your family member, you 
may have inherited this genetic risk factor. 
3. What will happen if I have the genetic risk factor? 
The genetic testing is able to identify if you have a specific genetic change that puts you at risk of 
developing the disease. However, this test cannot predict if you will develop the disease or exactly 
when. If you have this genetic risk factor, <Disease Specific Screenings> is recommended to enable 
early detection and treatment.  
4. What action should I take? 
We suggest you to have a genetic counselor evaluation to discuss about being tested for this genetic 
risk factor and/or to receive information for specific health screening. Genetic testing is the only 
way to know if you have the genetic risk factor. As the symptoms vary and can appear late in life, 
you may have a chance to develop <Disease Name> even if you do not think you have it. Your 
primary care provider can refer you to genetic counseling. Alternatively, you can find a genetic 
counselor through this website: www.findageneticcounselor.com 
 
Finally, if you have additional questions, need assistance finding a genetic counselor, or are 
interested in learning more about our genetic research studies, please feel free to contact us at 











To evaluate the fixed study startup cost of this pilot study, we calculated direct labor 
costs, converted into an annual full-time equivalent (FTE) based on individual 
compensation levels of the different study team members, in addition to the other direct 
and indirect costs involved in developing and implementing the Return of Results 
Workflow over 31 months.  
 
The study team was made up of eight individuals with different skill sets. They included 
four faculty members (3 nephrologists and 1 molecular pathologist), two research 
scientists, one research staff member (a trained clinical nephrologist who holds a 
position as “Project Coordinator Level II”) and one research trainee (the Precision 
Nephrology fellow, an ABIM board-certified nephrologist) sponsored by institutional 






Estimates of productivity (in hours) 
 
Labor costs were based on retrospective estimates of hours dedicated by each study 
member in the completion of specific tasks associated with developing the Return of 
Results Workflow (in study year 1 (2017): Y1) and then implementing it (in study years 2 
(2018) and 3 (2019): Y2 and Y3). Each study member was asked to provide a 
conservative approximation of hours (productivity) they dedicated to specific tasks, per 
calendar year (12 months). Tasks associated with this pilot study included: 
A. Development of the Return of Results Workflow (Y1) - 
Drafting and submitting the study amendments to the IRB, verifying that primary 
diagnostic findings were indeed explicative of the patient’s kidney disease and 
confirming the pathogenicity of the actionable secondary findings identified through our 
variant annotation pipeline, conducting in-depth review of each participants’ EHRs, 
defining the individual steps of the workflow in collaboration with clinicians, and 
developing communication and data management tools.  
-When available, hour estimates were cross-referenced with user logs (i.e., RedCap’s 
user activity monitoring). 
B. Implementation of the Return of Results Workflow (Y2, Y3) - 
Re-contacting attempts for participants (e.g., drafting letters, obtaining signatures from 
faculty members, labeling and mailing letters, calling study participants, coordinating in-
person visits for clinical re-testing and/or Return of Results visits, etc.), counseling and 
evaluating patients during up to two visits, processing specimens for clinical re-testing, 
reviewing the literature of the identified genetic syndromes to provide clinicians with up-
to-date management recommendations based on published evidence and consensus 
guidelines, drafting detailed consultation notes for providers, discussing cases with the 
 
 
referring nephrologists at different steps of the workflow (e.g., during case-level 
interpretation of candidate variants at “genetic sign out rounds”, at one-on-one meetings 
when implementing the genetic findings into clinical care, at monthly educational 
conferences intended to support nephrologists’ education, etc.), and coordinating 
subsequent patients’ follow-up care (e.g., arranging follow-up visits, referrals, familial 
testing, additional genetic counseling, entering data into the EHR, etc.).  
-Of note, for certain tasks (e.g., meeting patients for pre-test counseling, clinical 
consultation and post-test counseling, note writing) time logs were used prospectively, 
and the minimum and maximum time spent on those specific tasks, averaged. 
 
The hours provided by each study team member, performing each task, were then 
totaled and categorized by the individual’s compensation levels (e.g., faculty compared 
to research scientists/research staff compared to the research trainee). For example, if 
one faculty member spent 17 hours on one task, and the other three faculty members 
each spent an hour on the same task, the total hours dedicated to that specific task was 




Then, annual compensations (i.e., salary or training awards) were estimated for each 
member of the study teams. For faculty, a National Institute of Health (NIH) salary cap 
of $187,000 (for fiscal years 2017 and 2018) was used as a conservative estimate for 
the faculty members. In addition, Columbia University’s average annual salary for both 
research scientists, and research staff member who holds the position of “Project 
Coordinator, Level II” was $60,000 during the same fiscal years.  
 
The research trainee held a non-salary position. Thus, the direct costs per year for this 
study team member was based on the specific institutional research training awards the 
Precision Nephrology fellow received during those same years. Specifically, during Y1, 
the research trainee was supported by the Division’s T32 award, and the direct costs 
were $64,228/year, which included a stipend ($54,228), training related expenses (TRE) 
($4500), tuition fees ($4,500), and a travel budget ($1000). In Y2 and Y3, the research 
trainee was supported by Columbia University’s Clinical & Translational Science Awards 
(CTSA) program TL1 award, and the direct costs were $68,378/year, which included a 




Using Columbia University’s fringe rate of 30.3% (for 2017 through 2019 fiscal years), 
we added the fringe expense based on the direct salary of the faculty, research 
scientists and research staff members. The fringe expense was not added to the direct 
labor costs of the research trainee.  
 




Available hours were calculated based on institutional policies. For faculty and for the 
research trainee, the estimated time available for productive work was assumed to be 
2000 hours/year, based on 40 hours/week for 50 weeks/year, considering holidays, 
vacation and sick time. For the research scientists and the research staff member, 
available hours were estimated to be 1750 hours/year, based on 35 hours/week, for 50 
weeks/year.  
 
Finally, FTEs were calculated based on total hours dedicated to each task, divided by 
the available hours of each team member category (e.g., 2000 hours/year for the faculty 
and the research trainee versus 1750 hours/year for the research scientists and the 
research staff member). Direct labor costs were then calculated based on the FTE, at 
each level of compensation (i.e., faculty versus research scientists/research staff versus 
research trainee).  
 
 
2. Sequencing Costs: 
 
Other direct costs included the cost of targeted dideoxy terminator (Sanger) sequencing 
(rate based on the number of variants requiring clinical conformation), and shipment 
costs, for 30 samples that went to the NYGC for clinical re-testing. An additional 11 
samples were sent to Columbia University’s Personalized Genomics Laboratory for 
confirmatory Sanger sequencing (no associated shipment costs). The sequencing cost 
for the 7 study participants dual enrolled in the eMERGE study, was covered by the 
eMERGE Network. Since these patients were part of a large multicenter study, the 
individual sequencing costs for these 7 participants is not yet available, and therefore, 
was not included in this analysis. 
 
Of note, the cost of research-grade exome sequencing was $350 per exome, and was 
conducted by Columbia University’s Institute of Genomic Medicine. However, these 






Additional overhead expenses were also included in our calculations. Based on 
institutional policies, 60% indirect (overhead) costs (for fiscal years 2017 through 2019) 
was added to the salary with fringe for salaried study team members (e.g., faculty, 
research scientists and research staff members). This expense was not added for the 
research trainee. Instead, per NIH policy, Facilities and Administrative (F&A) costs of 
8% were added to the Precision Nephrology fellow’s direct trainee costs. 
 
 








Section S2- SUPPLEMENTARY RESULTS 
 
This is an ongoing sequencing study. To date, we identified 213 individuals with 
medically relevant findings, 205 (96%) of whom were included in earlier publications1, 2, 
while the remaining 8 participants were sequenced in the intervening periods.  
 
Reasons for participant ineligibility through the pilot workflow 
 
Reasons for ineligibility for recontact through this pilot workflow included the following: 
Pediatric (age < 18 years) participants will have results returned through a separate 
pediatrics workflow (n = 22); participants who did not opt to re-contact during time of 
original consent (n = 5); and participants enrolled prior to January 2015 who have not as 
of yet re-consented to the study with the revised consent form (n = 73). Of note, study 
participants consented prior to the protocol update are routinely notified of the new 
consent clause, and invited to re-consent with the new Return of Results option clause, 
when they present to nephrology follow-up appointments. Participants that are not 
reached in follow-up visits will be notified of the updated consent clause by mail 
correspondence and invited to update their preference on re-contact. Also, a Pediatric 
Return of Results Workflow is being developed for the re-contact of all pediatric cases. 
 
Of the remaining 113 adult participants, 9 additional participants were excluded after 
review of the EHR revealed these individuals had undergone clinical genetic testing, 
outside of the nephrology Return of Results Workflow, since the time of original 
enrollment. Interestingly, these 9 individuals had medically actionable secondary 
findings in genes included in the ACMG 59 list. Moreover, 6 of these 9 participants were 
dually recruited in the eMERGE Network’s Phase III study and therefore, also 
underwent clinical-grade sequencing using the NGS panel. As part of the eMERGE 
study, these 6 participants were notified of the positive findings by letter and invited to 
schedule a visit for post-test counseling with a genetic counselor, with field expertise in 
hereditary cardiovascular or cancer syndromes. Of note, eMERGE-participants with 
diagnostic (primary) findings explicative of their nephropathy, we included in this Return 
of Results Workflow.  
 
Importantly, for all 9 cases, clinical testing identified the same genetic finding detected 
in our study. These cases are described in further detail in Table S3. For all 9 
individuals’, their referring nephrologist was informed that research-grade ES identified 
the same genetic finding as the variant(s) identified by clinical genetic testing, so that 
they may inform the patient. Our pilot cohort was made up of the remaining 104 eligible 























EYA1 601653 Branchiootorenal syndrome 1 with or without cataracts 113650 2 
PAX2 167409 Glomerulosclerosis focal segmental 7; Papillorenal syndrome 616002; 120330 1 
PKD1 601313 Polycystic kidney disease 1 173900 2 
UMOD 191845 Autosomal dominant tubulointerstitial kidney disease, UMOD-associated 
609886;162000; 
603860 1 
HNF1B 189907 Renal cysts and diabetes syndrome 137920 1 
TSC1 605284 Tuberous sclerosis-1 191100 1 
PKHD1 606702 Polycystic kidney disease, autosomal recessive 263200 1 










CRB2 609720 Focal segmental glomerulosclerosis 9 616220 2 
COL4A3 120070 
Alport syndrome, autosomal 
dominant/recessive; Thin basement 
membrane disease 
203780; 141200 8 
COL4A4 120131 
Alport syndrome, autosomal 
dominant/recessive; Thin basement 
membrane disease 
203780; 141200 12 
COL4A5 303630 Alport syndrome, X-linked 301050 15 
INF2 610982 Glomerulosclerosis focal segmental 5 613237 1 
NPHS1 607100 Nephrotic syndrome type 1 256300 1 
NPHS2 600995 Nephrotic syndrome type 2 600995 1 
 
 
TRPC6 603652 Glomerulosclerosis focal segmental 2 603965 5 
WT1 607102 Nephrotic syndrome type 4 256370 1 
SALL1 602218 Townes-Brocks syndrome 1 107480 1 
CREBBP 600140 Rubinstein-Taybi syndrome 1 180849 1 
DSP 125647 Arrhythmogenic right ventricular dysplasia 8 604400 1 
SCN5A 600163 Brugada syndrome 1; Long QT syndrome 3 601144; 603830 1 
PMS2 600259 Colorectal cancer hereditary nonpolyposis type 4 614337 1 
BRCA2 600185 Breast-ovarian cancer, familial 2 612555 3 










HNF1A 142410 MODY type III 600496 2 
MYCN 164840 Feingold syndrome 1 164280 1 










ATP6V1B1 192132 Renal tubular acidosis with deafness 267300 1 
CLCN5 300008 Dent disease 300009 1 
SLC12A3 600968 Gitelman syndrome 263800 2 
SLC4A1 109270 Renal tubular acidosis distal, autosomal dominant 179800 1 
SLC5A2 182381 Renal glucosuria 233100 1 
UMOD 191845 Autosomal dominant tubulointerstitial kidney disease, UMOD-associated 
609886;162000; 
603860 4 
HNF1B 189907 Renal cysts and diabetes syndrome 137920 1 










APOE 107741 Lipoprotein glomerulopathy 611771 1 
 
 
CLCN5 300008 Dent disease 300009 3 
COL4A3 120070 
Alport syndrome, autosomal 
dominant/recessive; Thin basement 
membrane disease 
203780; 141200 1 
COL4A5 303630 Alport syndrome, X-linked 301050 2 
HBB 141900 Sickle cell disease 603903 1 
MC4R 155541 Obesity autosomal dominant 601665 1 
MYH9 160775 Epstein syndrome; Fechtner syndrome 153650; 153640 1 
NPHS2 600995 Nephrotic syndrome type 2 600995 1 
PKD1 601313 Polycystic kidney disease 1 173900 1 
PAX2 167409 Glomerulosclerosis focal segmental 7; Papillorenal syndrome 616002; 120330 2 
UMOD 191845 Autosomal dominant tubulointerstitial kidney disease, UMOD-associated 
609886;162000; 
603860 1 
NPHP4 607215 Nephronophthisis 4 606966 2 
COL4A5 303630 Alport syndrome, X-linked 301050 
1* 
NPHP3 607215 Nephronophthisis 3 604387 
HNF1A 142410 MODY type III 600496 1 
HNF4A 600281 MODY type 1 125850 1 
TRPC6 603652 Glomerulosclerosis focal segmental 2 603965 1 
PTPN11 176876 Noonan syndrome 1 163950 1 
PKHD1 606702 Polycystic kidney disease, autosomal recessive 263200 2 
PKP2 602861 Arrhythmogenic right ventricular dysplasia 9 609040 1 
BRCA2 600185 Breast-ovarian cancer, familial 2 612555 1 










GLA 300644 Fabry disease 301500 1 
 
*Patient with a dual molecular diagnoses 
 
 
Eight participants had known pathogenic variants in genes included in the ACMG 59 as 
medically actionable secondary findings: DSP (n = 1), SCN5A (n = 1), PKP2 (n = 1), 
PMS2 (n = 1), and in BRCA2 (n = 4). Ninety-six participants had primary diagnostic 
findings encompassing 34 genes, including one participant with dual molecular 
diagnoses (Alport syndrome, X-linked and Nephronophthisis 3). 
 
Note: The clinical diagnoses are displayed by rows. The eight participants with 








Description of case where the research-level genetic finding was not confirmed 
on clinical re-testing 
 
In one case of a female with a heterozygous deletion of exon 37 in COL4A5, the results 
were not confirmed due to a technical limitation of the confirmatory test modality used 
(i.e., limited analytical sensitivity for detection of copy number variations with Sanger 
sequencing). Due to the high suspicion that the research finding was causal, this patient 
was referred for genetic counseling to discuss the options for further clinical-grade 
genetic testing using a commercial panel with robust coverage of the relevant gene, 
which included deletion/duplication analysis of COL4A5. Ultimately, the patient chose to 
defer this option citing a lack of interest.  
 
 
Reasons for participants’ refusal to return for Return of Results  
 
Six individuals failed to return for their results. One participant failed to show up to a 
scheduled appointment (“No Show”) and could not be subsequently reached by 
telephone or email to re-schedule. Another individual did not want to schedule a return 
of results visit despite multiple attempts, twice citing a lack of time. The remaining four 
participants cited they were not interested in returning because they already knew their 
clinical diagnosis: One participant, diagnosed with FSGS, revealed they had previously 
undergone clinical-grade genetic testing through a different academic institution, and 
knew of the genetic finding in the TRPC6 gene, which was not documented in our 
hospital’s electronic health record; when asked, they stated they withheld this 
information because they wanted to “see if you would find the same variant”. Two 
individuals, both clinically diagnosed with Autosomal dominant Polycystic kidney 
disease (ADPKD), declined to comment regarding whether they too underwent clinical 
genetic testing. One participant with a diagnostic finding in UMOD also stated he knew 
his diagnosis clinically.  
 
 
For all 6 participants, the CLIA-confirmed findings were shared with their referring 
provider and entered into the electronic health record, either following the post-test 




Table S2: Fixed start-up costs for the development and implementation of the 
Return of Results Workflow in this pilot study 
 
In total, eight study team members worked approximately 1452 total hours to develop 
and implement the Return of Results Workflow for nephrology, over 31 months. The 
total fixed start-up cost for this pilot study was estimated to be $92,249.31. This includes 
$80,160.61 of total labor costs (direct + indirect).   
 
In Y1, approximately 406 hours were devoted to tasks relating to development of the 
workflow. Of the 406 hours, 44% (approximately 180 hours) was dedicated to genetic 
data analysis, which included variant-level and case-level review, while 23% 
(approximately 92 hours) was spent on the development of the communication tools 
(See Re-contact Letter, Re-contact Telephone Script, Nephrogenetics Consultation 
Note Template and Family Letter Template in Section S1). The total cost of Y1 was 
$30,675.51.  
 
During Y2 and Y3, approximately 1046 hours were devoted to the implementation of the 
workflow. Of the 1046 hours, 650 hours (62%) was dedicated to clinical application of 
the genetic findings (e.g., clinical evaluation with post-test counseling, literature review, 
coordinating follow-up care, meeting with faculty to discuss the genetic findings, etc.) for 
this pilot cohort. In addition, the cost of clinical genetic testing at the NYGC ranged from 
$250 to $450, depending on the number of variants validated. The cost of clinical re-
testing for 30 participants through the NYGC was $8,238.70 ($7900 for clinical 
sequencing of 34 variants in 30 participants; $338.70 for sample shipping). The cost of 
clinical genetic testing at Columbia University’s Personalized Genomics Laboratory was 
$350 for Sanger confirmation of a single variant. The cost of clinical re-testing for 11 
participants (11 variants) through the Personalized Genomics Laboratory was $3,850 
(no sample shipment required). Therefore, the total cost of clinical grade confirmatory 
sequencing for the 41 participants that only underwent research-grade ES was 
$12,088.70. The total estimated cost for Y2 and Y3 was $61,573.80. (Table S2).  
 
Note: Forty-one participants had only research-grade sequencing and required clinical 
re-testing that was done at a CLIA-certified laboratory (the New York Genome Center or 









Description Time (hours) 










(n = 2)/ 
Research 
Staff 




(n = 1) 
 
IRB Approval/ 
Amendments 74 0 0.01 0.03 0.04 $3,943.45 
Development of communication 
tools 92 0.01 0.01 0.03 0.05 $5,849.71 
Variant-level review 70 0.03 0.01 0 0.04 $12,410.52 
Training tools development 20 0 0.01 0 0.01 $1,429.58 
Recruitment personnel training 40 0 0.02 0 0.02 $2,859.15 
Clinical (Case-level) review 110 0 0.01 0.05 0.06 $4,183.10 
Return of Results 
Development 
Total in Y1 
406 0.04 0.07 0.11 0.21 $30,675.51 
RedCap design and production 100 0 0.01 0.05 0.05 $4,037.96 
Participant re-contact 100 0 0.01 0.05 0.05 $4,383.51 
Pre-test counseling 41 0 0.01 0.02 0.02 $1,859.44 
Clinical re-testing 20 0 0 0.01 0.01 $738.48 
Return of results 90 0.02 0 0.03 0.05 $9,643.36 
Clinical application of findings 650 0.01 0 0.33 0.33 $27,160.77 
Data entry/cleaning 45 0 0 0.02 0.02 $1,661.59 
Additional Direct Costs  - - - - - - 
CLIA-sequencing  N/A N/A N/A N/A N/A $11,750.00 
Specimen shipment  N/A N/A N/A N/A N/A $338.70 
Return of Results 
Implementation  
Total in Y2 and Y3   
1046 0.03 0.02 0.47 0.53 $61,573.80 
Total 1452 0.07 0.09 0.58 0.74 $92,249.31 
 
*Total costs include direct labor costs (Salary with Fringe (30.3%) and indirect costs 
(60% overhead) for faculty, research scientists and research staff; the research 







Table S3: Faculty (Salary)-  





Salary Fringe  expense 
Indirect 
costs* Total labor 
costs** 
$187,000 30.3% 60%  
IRB Approval/ 
Amendments 4 0.00 $374.00 $113.32 $292.39 $779.72 
Development of 
communication tools  12 0.01 $1,122.00 $339.97 $877.18 $2,339.15 
Variant-level review 60 0.03 $5,610.00 $1,699.83 $4,385.90 $11,695.73 
Training tool development 0 - - - - - 
Recruitment personnel 
training 0 - - - - - 
Clinical case review 0 - - - - - 
RedCap design and 
production 0 - - - - - 
Participant re-contact 0 - - - - - 
Pre-test counseling 0 - - - - - 
Clinical re-testing 0 - - - - - 
Return of results 40 0.02 $3,740.00 $1,133.22 $2,923.93 $7,797.15 
Clinical application of findings 20 0.01 $1,870.00 $566.61 $1,461.97 $3,898.58 
Data entry/cleaning 0 - - - - - 
TOTAL Y1 & Y2 & Y3 136 0.07 $12,716.00 $3,852.95 $9,941.37 $26,510.32 
 
 
*Indirect costs: 60% overhead costs 











Table S4: Research Scientists/Research Staff (Salary)-  
Hours, FTE and Direct Costs with Fringe + Indirect Costs 
 
Description 
Research Scientists/Project Coordinator (Level II) 
Hours FTE 
Salary Fringe expense 
Indirect 
costs* Total labor 
costs** 
$60,000 30.3% 60% 
IRB Approval/Amendments 20 0.01 $685.71 $207.77 $536.09 $1,429.58 
Development of 
communication tools 20 0.01 $685.71 $207.77 $536.09 $1,429.58 
Variant-level review 10 0.01 $342.86 $103.89 $268.05 $714.79 
Training tools development 20 0.01 $685.71 $207.77 $536.09 $1,429.58 
Recruitment personnel training 40 0.02 $1,371.43 $415.54 $1,072.18 $2,859.15 
Clinical case review 10 0.01 $342.86 $103.89 $268.05 $714.79 
RedCap design and 
production 10 0.01 $342.86 $103.89 $268.05 $714.79 
Participant re-contact 20 0.01 $685.71 $207.77 $536.09 $1,429.58 
Pre-test counseling 10 0.01 $342.86 $103.89 $268.05 $714.79 
Clinical re-testing 0 - - - - - 
Return of results 0 - - - - - 
Clinical application of findings 0 - - - - - 
Data entry/cleaning 0 - - - - - 




*Indirect costs: 60% overhead costs 









Table S5: Research trainee (Precision Nephrology Fellow)- 
Hours, FTE and Direct Trainee costs + Indirect Costs 
 
Description 







costs* Total labor 




IRB Approval/Amendments 50 0.03 $685.71 - $128.46 $1,734.16 
Development of 
communication tools 60 0.03 $685.71 - $154.15 $2,080.99 
Variant-level review 0 - $342.86 - - - 
Training tools development 0 - $685.71 - - - 
Recruitment personnel 
training 0 - $1,371.43 - - - 
Clinical case review 100 0.05 $3,211.40 - $256.91 $3,468.31 
RedCap design and 
production 90 0.05 $3,077.01 - $246.16 $3,323.17 
Participant re-contact 80 0.04 $2,735.12 - $218.81 $2,953.93 
Pre-test counseling 31 0.02 $1,059.86 - $84.79 $1,144.65 
Clinical re-testing 20 0.01 $683.78 - $54.70 $738.48 
Return of results 50 0.03 $1,709.45 - $136.76 $1,846.21 
Clinical application of 
findings 630 0.32 $21,539.07 - $1,723.13 $23,262.20 
Data entry/cleaning 45 0.02 $1,538.51 - $123.08 $1,661.59 
TOTAL Y1 & Y2 & Y3 1,156 0.58 $   39,086.73 - $3,126.94 $42,213.67 
 
 
*Indirect costs: 8% F&A costs 







Table S6: Examples of the clinical utility of ACMG 59 genes in participants who 
underwent clinical genetic testing and had their genetic results returned outside 
of the Return of Results Workflow 
 
Below are 9 participants, excluded in the pilot cohort, who had known pathogenic 
variants in the 59 genes recommended by the ACMG for return as medically actionable 
secondary findings for individuals undergoing genome-wide sequencing10. These 
patients underwent clinical genetic testing and were found to have the same genetic 
findings as the one we detected on research-grade ES. There clinically confirmed 
results were returned outside of this workflow. To further assess the opportunities and 
challenges of assessing genetic results, including the capacity of genome-wide 
sequencing to detect variants diagnostic for otherwise medically actionable conditions 
not directly explicative for patients’ nephropathy, we conducted a broader survey of 
cases who had participated in our genetic study. Therefore, to determine the clinical 
implications of the genetic diagnoses on nephrology care in these 9 cases, we 
assessed: 1) the extent of the known phenotypic concordance (the column, “Known 
Clinical Features Consistent with the ACMG 59 Gene Disorder”); 2) the greater 
implications of these genetic findings to their care, such as surveillance and/or 
management strategies available based on the findings (column titled “Clinical 
Implications”); and 3) the potential implications of the findings to nephrologic care (in the 
column, “Potential Implications for Nephrologic care”) based on review of the literature 
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CKD: Chronic Kidney Disease; HTN: Hypertension; VTE: Venous thromboembolism; 
s/p: status-post; AVR: Aortic valve replacement; AICD: Automatic implantable 
cardioverter-defibrillator; DDRT: Deceased donor kidney transplant; CAD: Coronary 
artery disease; CABG: Coronary artery bypass grafting; CVA: Cerebrovascular 
accident; DM: diabetes mellitus; LDL: Low-density lipoprotein  
 
*Use of statin therapy for cardioprotection in CKD and kidney failure populations has 
been studied in three prospective studies: 4D Study (diabetes mellitus and Kidney 
failure)33; AURORA Study (Kidney failure)34; SHARP Study (CKD, Kidney failure)35. 
Based on these findings, and various post-hoc analyses, the 2013 Kidney Disease: 
Improving Global Outcomes (KDIGO)36 guidelines did not recommend initiation of statin 
treatment in dialysis patients, but agreed with continuing statin therapy if patients 
already on statins. In 2015, the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (KDOQI) working group convened and issued a commentary in 
agreement with that position37. The 2018 American College of Cardiology and American 
Heart Association Task Force issued Clinical Practice Guidelines for Cholesterol 
management32 also agreed with this recommendation. However, these guidelines also 
identified CKD (eGFR 15-59 mL/min/1.73m2) and Heterozygous Familial 
Hypercholesterolemia as high-risk conditions. Therefore, identifying CKD and kidney 
failure patients with Familial Hypercholesterolemia is a priority, and further study is 
needed to determine if treatment escalation with higher doses of statin and use of 
adjuvant therapies (e.g., ezetimibe, PCSK9 Inhibitors, etc.) for lower LDL-level targets 
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